Increases in cancer incidence and rising cancer costs highlight the need to advance cancer biology through the growth of a well-trained workforce. City of Hope, an NCI-designated Comprehensive Cancer Center, is known internationally for clinical cancer research and has an outstanding record of research in the basic sciences, with an emphasis on cancer research. Therefore, this proposed program, supported by the robust cancer research environment at City of Hope, is dedicated to training young scientists in a setting that will prepare them to become leaders in cancer research. Almost all human cancers have alterations in signaling pathways associated with DNA damage response and oncogenic signaling (DDROS). Therefore, to develop the next generation of cancer researchers, a multidisciplinary, institution-wide cancer biology training program is proposed to train postdoctoral fellows in DDROS. The 3 T32-supported postdoctoral trainees supported for up to 3 years will be selected for the DDROS program through a rigorous process, including a personal interview. Annual reappointment will be based on annual written reports, mentor reports, and presentations. Each trainee will establish a mentoring committee that will include a physician to favor the cross-pollination of ideas between the basic and translational aspects of cancer research. As part of an incentive to the DDROS program, City of Hope will provide an additional postdoctoral trainee position for every underrepresented minority trainee recruited, up to a total of 6 positions. Furthermore, to attract the best postdoctoral candidates at a national level, City of Hope will commit to salary supplementation for all DDROS trainees, a stipend for research supplies, and full administrative and faculty salary support. In this highly collaborative environment, trainees will have the opportunity to participate in multidisciplinary research that seeks to translate innovative basic research findings into powerful methods for preventing or treating cancer. Trainees will be mentored by 18 faculty members, all of whom are performing cancer-focused, funded, high-impact research in DDROS and have a history of mentoring postdoctoral fellows. To enhance their chances of securing academic positions, all DDROS trainees will take a unique common curriculum that provides a continuum of learning including scientific coursework, professional development, and the ethical conduct of research. In addition, trainees will participate in cutting-edge research programs, journal clubs, data clubs, seminars, symposiums, monthly luncheons with mentors, workshops, national and international scientific conferences, and finally a yearly DDROS Symposium. The stellar 29 Shared Resource Facilities associated with the Cancer Center will also provide training in state-of the art technologies. The request for funding of this research training grant is justified by the relevance of the research training to cancer, the exceptional environment for the overlap of basic and translational cancer research, the superb experience of the mentors in training, the outstanding commitment of City of Hope, and the diverse population of the geographical area served by our institution.
In order to support the development of novel anti-cancer therapies, we propose a multidisciplinary, institution- wide cancer biology T32 postdoctoral training program at City of Hope (Duarte, CA) to prepare exceptionally motivated postdoctoral fellows in the fields of DNA damage response and oncogenic signaling (DDROS). Because cancer disproportionately impacts minority populations in the US, we have designed a strategy, which is aided by exceptional institutional support for salaries and research funds, to emphasize attracting and training scientists from underrepresented minority (URM) backgrounds. With our collection of outstanding DDROS researchers and physician collaborators, state of the art facilities, strong curriculum, emphasis on obtaining extramural funding, and superb institutional support, we are poised to initiate this new DDROS program, which will train the next generation of leaders in the fight against cancer.
|Tran, Thai Q; Ishak Gabra, Mari B; Lowman, Xazmin H et al. (2017) Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes. PLoS Biol 15:e2002810|
|Hanse, E A; Ruan, C; Kachman, M et al. (2017) Cytosolic malate dehydrogenase activity helps support glycolysis in actively proliferating cells and cancer. Oncogene 36:3915-3924|
|Tran, T Q; Lowman, X H; Reid, M A et al. (2017) Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene 36:1991-2001|
|Tran, Thai Q; Lowman, Xazmin H; Kong, Mei (2017) Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer. Clin Cancer Res 23:4004-4009|
|Al-Hadid, Qais; Yang, Yanzhong (2016) R-loop: an emerging regulator of chromatin dynamics. Acta Biochim Biophys Sin (Shanghai) 48:623-31|
|Reid, Michael A; Lowman, Xazmin H; Pan, Min et al. (2016) IKK? promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3. Genes Dev 30:1837-51|
|Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-? induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42|